Strs Ohio Buys 3,200 Shares of Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA)

Strs Ohio lifted its stake in Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA) by 20.6% during the 4th quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The fund owned 18,700 shares of the biotechnology company’s stock after purchasing an additional 3,200 shares during the period. Strs Ohio owned 0.09% of Enanta Pharmaceuticals worth $175,000 at the end of the most recent quarter.

Several other hedge funds and other institutional investors have also made changes to their positions in the stock. Nisa Investment Advisors LLC lifted its holdings in Enanta Pharmaceuticals by 417.8% during the fourth quarter. Nisa Investment Advisors LLC now owns 2,827 shares of the biotechnology company’s stock worth $27,000 after acquiring an additional 2,281 shares in the last quarter. Clearstead Advisors LLC bought a new position in Enanta Pharmaceuticals during the third quarter worth about $57,000. Quantbot Technologies LP lifted its holdings in Enanta Pharmaceuticals by 2,300.0% during the third quarter. Quantbot Technologies LP now owns 7,200 shares of the biotechnology company’s stock worth $80,000 after acquiring an additional 6,900 shares in the last quarter. Sherbrooke Park Advisers LLC bought a new position in Enanta Pharmaceuticals during the third quarter worth about $113,000. Finally, Laurion Capital Management LP bought a new position in Enanta Pharmaceuticals during the third quarter worth about $126,000. 94.99% of the stock is currently owned by institutional investors.

Enanta Pharmaceuticals Price Performance

Shares of Enanta Pharmaceuticals stock opened at $13.74 on Wednesday. The firm has a market cap of $290.74 million, a price-to-earnings ratio of -2.09 and a beta of 0.47. The stock’s 50-day moving average is $14.85 and its 200-day moving average is $11.92. Enanta Pharmaceuticals, Inc. has a one year low of $8.08 and a one year high of $37.75.

Enanta Pharmaceuticals (NASDAQ:ENTA) last released its earnings results on Wednesday, February 7th. The biotechnology company reported ($1.58) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($1.18) by ($0.40). The company had revenue of $18.00 million during the quarter, compared to analyst estimates of $22.74 million. Enanta Pharmaceuticals had a negative net margin of 187.77% and a negative return on equity of 60.38%. On average, equities analysts expect that Enanta Pharmaceuticals, Inc. will post -4.9 EPS for the current year.

Wall Street Analyst Weigh In

Several research analysts have weighed in on ENTA shares. JPMorgan Chase & Co. reduced their target price on Enanta Pharmaceuticals from $12.00 to $11.00 and set an “underweight” rating on the stock in a report on Thursday, February 8th. StockNews.com lowered Enanta Pharmaceuticals from a “hold” rating to a “sell” rating in a report on Saturday, April 6th. Two equities research analysts have rated the stock with a sell rating, three have issued a hold rating and two have issued a buy rating to the company. Based on data from MarketBeat, the stock has an average rating of “Hold” and an average price target of $19.33.

About Enanta Pharmaceuticals

Enanta Pharmaceuticals, Inc, a biotechnology company, discovers and develops small molecule drugs for the treatment of viral infections and liver diseases. Its product pipeline comprises EDP-514, which is in phase 1b clinical development for the treatment of chronic infection with hepatitis B virus or HBV; EDP-938 and EDP-323, which is in phase II clinical development for the treatment of respiratory syncytial virus; EDP-235, which is in phase II clinical development for the treatment of human coronaviruses; and Glecaprevir, which is in the market for the treatment of chronic infection with hepatitis C virus or HCV.